retatrutide clinical trials efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Substack Series 3 of 6:

Peptide Therapy Ipamorelin, NAD+, and blends for performance and recovery

Incomplete resections (R1 or R2) are associated with a significantly higher risk of recurrence (Evans et al., 2021)

Consumers exiting GLP-1 therapies are looking for maintenance solutions to sustain their weight loss without medication

Patients should also be aware of rare but serious risks including pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, particularly with rapid improvement in glucose control

Diabetes & metabolism

A broad spectrum of carotenoids (lutein, zeaxanthin, lycopene, astaxanthin) accumulate in skin tissue, functioning as singlet oxygen quenchers and lipid-phase antioxidants that attenuate ROS propagation